{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:02:46Z","timestamp":1792785766124,"version":"4.5.0"},"reference-count":70,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministero della Salute Italy, Ricerca Corrente","award":["RC2025 260\/01"],"award-info":[{"award-number":["RC2025 260\/01"]}],"id":[{"id":"https:\/\/ror.org\/00789fa95","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Policlinico Milano and Regione Lombardia RICERCA SULLA FIBROSI CISTICA","award":["DRG17034 \/2024"],"award-info":[{"award-number":["DRG17034 \/2024"]}],"id":[{"id":"https:\/\/ror.org\/020dw9k11","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Policlinico Milano and Regione Lombardia RICERCA SULLA FIBROSI CISTICA","award":["RL_RLAOOG1_2025_9528"],"award-info":[{"award-number":["RL_RLAOOG1_2025_9528"]}],"id":[{"id":"https:\/\/ror.org\/020dw9k11","id-type":"ROR","asserted-by":"crossref"}]},{"name":"German Federal Ministry of Research Technology and Space","award":["82DZL009C1"],"award-info":[{"award-number":["82DZL009C1"]}],"id":[{"id":"https:\/\/ror.org\/04pz7b180","id-type":"ROR","asserted-by":"crossref"}]},{"name":"German Federal Ministry of Research Technology and Space","award":["01GL2401A"],"award-info":[{"award-number":["01GL2401A"]}],"id":[{"id":"https:\/\/ror.org\/04pz7b180","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["CRC 1449"],"award-info":[{"award-number":["CRC 1449"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["431232613"],"award-info":[{"award-number":["431232613"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["EXC 3118\/1"],"award-info":[{"award-number":["EXC 3118\/1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["533770413"],"award-info":[{"award-number":["533770413"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The advent of cystic fibrosis transmembrane conductance regulator (CFTR) modulators is fundamentally reshaping research and care for people with cystic fibrosis (CF). Despite unprecedented improvements in lung function and predicted survival, a substantial proportion of people with CF continue to exhibit residual disease activity (RDA) across multiple biological and clinical domains. Persistent abnormalities in CFTR function, mucus properties, mucociliary clearance, airway infection, inflammation, and symptom burden indicate that CFTR modulation does not fully normalize airway physiology or eliminate the pathological processes underlying CF lung disease. This review proposes RDA as a conceptual framework for identifying ongoing, potentially modifiable disease processes in people receiving CFTR modulators. Candidate measures across complementary mechanistic and clinical domains are examined, and their potential multidimensional interpretation as a means of supporting more individualized monitoring and treatment decisions is discussed. We consider the implications of RDA for clinical research by identifying key evidence gaps, outlining a stepwise pathway for its definition and validation. We further explore the potential to inform sensitive endpoint selection, enrich study populations, and guide the development of therapies targeting disease processes that persist despite CFTR modulation. As the CF population ages and disease trajectories evolve, care models and research priorities must move beyond conventional measures of disease severity alone. A better understanding and systematic evaluation of RDA may help align long-term clinical management and future trial design with the changing needs of people with CF, while ensuring that therapeutic advances translate into sustained health gains.<\/jats:p>","DOI":"10.1093\/ajrccm\/aamag370","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T11:57:47Z","timestamp":1783684667000},"page":"2530-2541","source":"Crossref","is-referenced-by-count":0,"title":["Residual disease activity in cystic fibrosis lung disease: implications for clinical management and research"],"prefix":"10.1093","volume":"212","author":[{"given":"Andrea","family":"Gramegna","sequence":"first","affiliation":[{"name":"Department of Pathophysiology and Transplantation, Universit\u00e0 degli Studi di Milano , Milan,","place":["Italy"]},{"name":"Respiratory and Cystic Fibrosis Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmarco","family":"Putti","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology and Transplantation, Universit\u00e0 degli Studi di Milano , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0430-2714","authenticated-orcid":false,"given":"Gianfranco","family":"Alicandro","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology and Transplantation, Universit\u00e0 degli Studi di Milano , Milan,","place":["Italy"]},{"name":"Mother and Child Department, Cystic Fibrosis Centre, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4057-2199","authenticated-orcid":false,"given":"Marcus A","family":"Mall","sequence":"additional","affiliation":[{"name":"Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin , Berlin,","place":["Germany"]},{"name":"German Center for Child and Adolescent Health (DZKJ), Partner Site Berlin , Berlin,","place":["Germany"]},{"name":"German Center for Lung Research (DZL), Associated Partner Site Berlin , Berlin,","place":["Germany"]},{"name":"Cluster of Excellence ImmunoPreCept, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin , Berlin,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Blasi","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology and Transplantation, Universit\u00e0 degli Studi di Milano , Milan,","place":["Italy"]},{"name":"Respiratory and Cystic Fibrosis Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico , Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"key":"2026101013470021000_aamag370-B1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41572-024-00538-6","article-title":"Cystic fibrosis","volume":"10","author":"Mall","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"2026101013470021000_aamag370-B2","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for cystic fibrosis Phe508del-gating and -residual function genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N Engl J Med"},{"key":"2026101013470021000_aamag370-B3","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S2213-2600(24)00411-9","article-title":"Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials","volume":"13","author":"Keating","year":"2025","journal-title":"Lancet Respir Med"},{"key":"2026101013470021000_aamag370-B4","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/S2213-2600(24)00208-X","article-title":"The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study","volume":"12","author":"Burgel","year":"2024","journal-title":"Lancet Respir Med"},{"key":"2026101013470021000_aamag370-B5","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"2026101013470021000_aamag370-B6","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"2026101013470021000_aamag370-B7","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026101013470021000_aamag370-B8","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1164\/rccm.202201-0219OC","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on lung clearance index and magnetic resonance imaging in patients with cystic fibrosis and one or two f508del alleles","volume":"206","author":"Graeber","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026101013470021000_aamag370-B9","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1164\/rccm.202308-1317OC","article-title":"Improvement in lung clearance index and chest computed tomography scores with elexacaftor\/tezacaftor\/ivacaftor treatment in people with cystic fibrosis aged 12 years and older\u2014the RECOVER trial","volume":"208","author":"McNally","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026101013470021000_aamag370-B10","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1164\/rccm.202011-4153OC","article-title":"Rapid improvement after starting elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis and advanced pulmonary disease","volume":"204","author":"Burgel","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2026101013470021000_aamag370-B11","doi-asserted-by":"publisher","first-page":"2501783","DOI":"10.1183\/13993003.01783-2025","article-title":"Advances in cystic fibrosis: CFTR modulator triple combinations","volume":"67","author":"Burgel","year":"2026","journal-title":"Eur Respir J"},{"key":"2026101013470021000_aamag370-B12","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1093\/ajrccm\/aamaf001","article-title":"Elexacaftor\/tezacaftor\/ivacaftor for cystic fibrosis and rare CFTR variants: in vitro translation to a phase 3, double-blind, randomized, placebo-controlled trial and real-world study","volume":"212","author":"Castellani","year":"2026","journal-title":"Am J Respir Crit Care Med"},{"key":"2026101013470021000_aamag370-B13","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jcf.2023.02.004","article-title":"Elexacaftor\/tezacaftor\/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del","volume":"22","author":"Lopez","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2026101013470021000_aamag370-B14","doi-asserted-by":"publisher","first-page":"240071","DOI":"10.1183\/16000617.0071-2024","article-title":"The ageing of people living with cystic fibrosis: what to expect now?","volume":"33","author":"Felipe Montiel","year":"2024","journal-title":"Eur Respir Rev"},{"key":"2026101013470021000_aamag370-B15","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1164\/rccm.202202-0392OC","article-title":"Efficacy and safety of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis heterozygous for F508del and a minimal function mutation: a phase 3b, randomized, placebo-controlled study","volume":"206","author":"Mall","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026101013470021000_aamag370-B16","doi-asserted-by":"publisher","first-page":"2402435","DOI":"10.1183\/13993003.02435-2024","article-title":"Elexacaftor\/tezacaftor\/ivacaftor in children aged \u22656 years with cystic fibrosis heterozygous for F508del and a minimal function mutation: results from a 96-week open-label extension study","volume":"66","author":"Mall","year":"2025","journal-title":"Eur Respir J"},{"key":"2026101013470021000_aamag370-B17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1164\/rccm.202301-0084OC","article-title":"Phase 3 open-label clinical trial of elexacaftor\/tezacaftor\/ivacaftor in children aged 2-5 years with cystic fibrosis and at least one F508del allele","volume":"208","author":"Goralski","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026101013470021000_aamag370-B18","doi-asserted-by":"publisher","first-page":"2400004","DOI":"10.1183\/13993003.00004-2024","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor therapy on lung clearance index and magnetic resonance imaging in children with cystic fibrosis and one or two F508del alleles","volume":"64","author":"Stahl","year":"2024","journal-title":"Eur Respir J"},{"key":"2026101013470021000_aamag370-B19","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1164\/rccm.202406-1254CI","article-title":"Is disease stability an attainable chronic obstructive pulmonary disease treatment goal?","volume":"211","author":"Singh","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"2026101013470021000_aamag370-B20","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1002\/acr.25690","article-title":"2025 American College of Rheumatology (ACR) guideline for the treatment of systemic lupus erythematosus","volume":"78","author":"Sammaritano","year":"2026","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026101013470021000_aamag370-B21","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/acr.24042","article-title":"2019 update of the American College of Rheumatology recommended rheumatoid arthritis disease activity measures","volume":"71","author":"England","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026101013470021000_aamag370-B22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.4046\/trd.2024.0120","article-title":"Disease severity and activity in bronchiectasis: a paradigm shift in bronchiectasis management","volume":"88","author":"Im","year":"2025","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"2026101013470021000_aamag370-B23","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1183\/09031936.00166412","article-title":"Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS patient registry","volume":"43","author":"Kerem","year":"2014","journal-title":"Eur Respir J"},{"key":"2026101013470021000_aamag370-B24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.cell.2020.11.034","article-title":"Hallmarks of health","volume":"184","author":"L\u00f3pez-Ot\u00edn","year":"2021","journal-title":"Cell"},{"key":"2026101013470021000_aamag370-B25","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.jcf.2024.04.013","article-title":"Heterogeneity in response to elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis","volume":"23","author":"Alicandro","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2026101013470021000_aamag370-B26","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.jcf.2024.02.001","article-title":"Heterogeneity of CFTR modulator-induced sweat chloride concentrations in people with cystic fibrosis","volume":"23","author":"Zemanick","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2026101013470021000_aamag370-B27","doi-asserted-by":"publisher","first-page":"00587","DOI":"10.1183\/23120541.00587-2024","article-title":"Variability in disease severity among cystic fibrosis patients carrying residual-function variants: data from the European Cystic Fibrosis Society Patient Registry","volume":"11","author":"Mei-Zahav","year":"2025","journal-title":"ERJ Open Res"},{"key":"2026101013470021000_aamag370-B28","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jcf.2024.12.006","article-title":"Sweat chloride reflects CFTR function and correlates with clinical outcomes following CFTR modulator treatment","volume":"24","author":"Zemanick","year":"2025","journal-title":"J Cyst Fibros"},{"key":"2026101013470021000_aamag370-B29","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1164\/rccm.202110-2249OC","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on CFTR function in patients with cystic fibrosis and one or two F508del alleles","volume":"205","author":"Graeber","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026101013470021000_aamag370-B30","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1164\/rccm.200509-1377OC","article-title":"Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials","volume":"174","author":"Wilschanski","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2026101013470021000_aamag370-B31","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1053\/j.gastro.2004.07.006","article-title":"CFTR Cl-channel function in native human colon correlates with the genotype and phenotype in cystic fibrosis","volume":"127","author":"Hirtz","year":"2004","journal-title":"Gastroenterology"},{"key":"2026101013470021000_aamag370-B32","doi-asserted-by":"publisher","first-page":"2202153","DOI":"10.1183\/13993003.02153-2022","article-title":"Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis","volume":"62","author":"Schaupp","year":"2023","journal-title":"Eur Respir J"},{"key":"2026101013470021000_aamag370-B33","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jcf.2023.12.002","article-title":"Standards for the care of people with cystic fibrosis; establishing and maintaining health","volume":"23","author":"Southern","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2026101013470021000_aamag370-B34","doi-asserted-by":"publisher","first-page":"2500616","DOI":"10.1183\/13993003.00616-2025","article-title":"Changes in sputum viscoelastic properties and airway inflammation in primary ciliary dyskinesia are comparable to cystic fibrosis on elexacaftor\/tezacaftor\/ivacaftor therapy","volume":"67","author":"Nussstein","year":"2026","journal-title":"Eur Respir J"},{"key":"2026101013470021000_aamag370-B35","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jcf.2023.10.010","article-title":"Effect of elexacaftor\/tezacaftor\/ivacaftor on mucus and mucociliary clearance in cystic fibrosis","volume":"23","author":"Donaldson","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2026101013470021000_aamag370-B36","doi-asserted-by":"publisher","first-page":"108464","DOI":"10.1016\/j.rmed.2025.108464","article-title":"Discontinuation of supportive therapies in people with cystic fibrosis treated with elexacaftor\/tezacaftor\/ivacaftor\u2014a patient-reported outcomes\u2019 study","volume":"249","author":"Ahting","year":"2025","journal-title":"Respir Med"},{"key":"2026101013470021000_aamag370-B37","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.chest.2024.03.033","article-title":"Relationship between lung volumes and heterogeneity in the response to elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis and advanced lung disease","volume":"166","author":"Gramegna","year":"2024","journal-title":"Chest"},{"key":"2026101013470021000_aamag370-B38","doi-asserted-by":"publisher","first-page":"2301794","DOI":"10.1183\/13993003.01794-2023","article-title":"Reversal of cylindrical bronchial dilatations in a subset of adults with cystic fibrosis treated with elexacaftor\/tezacaftor\/ivacaftor","volume":"63","author":"Cazier","year":"2024","journal-title":"Eur Respir J"},{"key":"2026101013470021000_aamag370-B39","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S2213-2600(25)00248-6","article-title":"Effect of elexacaftor-tezacaftor-ivacaftor on bronchial dilatations in adolescents with cystic fibrosis: a multicentre prospective observational study","volume":"14","author":"Sermet-Gaudelus","year":"2026","journal-title":"Lancet Respir Med"},{"key":"2026101013470021000_aamag370-B40","doi-asserted-by":"publisher","first-page":"e184171","DOI":"10.1172\/JCI184171","article-title":"Elexacaftor\/tezacaftor\/ivacaftor\u2019s effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatment","volume":"134","author":"Morgan","year":"2024","journal-title":"J Clin Invest"},{"key":"2026101013470021000_aamag370-B41","doi-asserted-by":"publisher","first-page":"240068","DOI":"10.1183\/16000617.0068-2024","article-title":"Changing profile of bacterial infection and microbiome in cystic fibrosis: when to use antibiotics in the era of CFTR-modulator therapy","volume":"33","author":"Milczewska","year":"2024","journal-title":"Eur Respir Rev"},{"key":"2026101013470021000_aamag370-B42","doi-asserted-by":"publisher","first-page":"885822","DOI":"10.3389\/fmicb.2022.885822","article-title":"Changes in microbiome dominance are associated with declining lung function and fluctuating inflammation in people with cystic fibrosis","volume":"13","author":"Frey","year":"2022","journal-title":"Front Microbiol"},{"key":"2026101013470021000_aamag370-B43","doi-asserted-by":"publisher","first-page":"e536","DOI":"10.1093\/infdis\/jiae051","article-title":"Impact of CFTR modulation on Pseudomonas aeruginosa infection in people with cystic fibrosis","volume":"230","author":"Ledger","year":"2024","journal-title":"J Infect Dis"},{"key":"2026101013470021000_aamag370-B44","doi-asserted-by":"publisher","first-page":"2500054","DOI":"10.1183\/13993003.00054-2025","article-title":"Sputum metagenomics in bronchiectasis reveals pan-European variation: an EMBARC-BRIDGE study","volume":"66","author":"Thng","year":"2025","journal-title":"Eur Respir J"},{"key":"2026101013470021000_aamag370-B45","doi-asserted-by":"publisher","first-page":"2501349","DOI":"10.1183\/13993003.01349-2025","article-title":"Characteristics, treatment and lung function outcomes of pulmonary exacerbations in cystic fibrosis: insights from the BEAT-CF cohort","volume":"67","author":"Fathima","year":"2026","journal-title":"Eur Respir J"},{"key":"2026101013470021000_aamag370-B46","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.jcf.2025.11.010","article-title":"Differences in pulmonary exacerbation risks among CF subpopulations","volume":"25","author":"VanDevanter","year":"2026","journal-title":"J Cyst Fibros"},{"key":"2026101013470021000_aamag370-B47","doi-asserted-by":"publisher","first-page":"2500150","DOI":"10.1183\/13993003.00150-2025","article-title":"Reduction of systemic inflammation by elexacaftor\/tezacaftor\/ivacaftor correlates with lung function improvement in cystic fibrosis","volume":"66","author":"Halle","year":"2025","journal-title":"Eur Respir J"},{"key":"2026101013470021000_aamag370-B48","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1136\/thorax-2022-219943","article-title":"Effect of elexacaftor\/tezacaftor\/ivacaftor on airway and systemic inflammation in cystic fibrosis","volume":"78","author":"Casey","year":"2023","journal-title":"Thorax"},{"key":"2026101013470021000_aamag370-B49","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1164\/rccm.202310-1836OC","article-title":"Pharmacological improvement of cystic fibrosis transmembrane conductance regulator function rescues airway epithelial homeostasis and host defense in children with cystic fibrosis","volume":"209","author":"Loske","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026101013470021000_aamag370-B50","doi-asserted-by":"publisher","first-page":"e196018","DOI":"10.1172\/jci.insight.196018","article-title":"Transcriptomic and functional responses of the cystic fibrosis airway epithelium to CFTR modulator therapy","volume":"10","author":"Vladar","year":"2025","journal-title":"JCI Insight"},{"key":"2026101013470021000_aamag370-B51","doi-asserted-by":"publisher","first-page":"e167957","DOI":"10.1172\/JCI167957","article-title":"Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist","volume":"133","author":"Nichols","year":"2023","journal-title":"J Clin Invest"},{"key":"2026101013470021000_aamag370-B52","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1164\/rccm.201609-1954OC","article-title":"Restoring cystic fibrosis transmembrane conductance regulator function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections","volume":"195","author":"Hisert","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2026101013470021000_aamag370-B53","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1183\/09031936.00163208","article-title":"Sputum colour: a useful clinical tool in non-cystic fibrosis bronchiectasis","volume":"34","author":"Murray","year":"2009","journal-title":"Eur Respir J"},{"key":"2026101013470021000_aamag370-B54","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/resp.12219","article-title":"The sputum colour chart as a predictor of lung inflammation, proteolysis and damage in non-cystic fibrosis bronchiectasis: a case-control analysis","volume":"19","author":"Goeminne","year":"2014","journal-title":"Respirology"},{"key":"2026101013470021000_aamag370-B55","doi-asserted-by":"publisher","first-page":"2301554","DOI":"10.1183\/13993003.01554-2023","article-title":"Objective sputum colour assessment and clinical outcomes in bronchiectasis: data from the European Bronchi\u00adectasis Registry (EMBARC)","volume":"63","author":"Aliberti","year":"2024","journal-title":"Eur Respir J"},{"key":"2026101013470021000_aamag370-B56","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.jcf.2025.11.014","article-title":"Improvements in health-related quality of life in people with cystic fibrosis \u22656 years of age treated with vanzacaftor\/tezacaftor\/deutivacaftor","volume":"25","author":"Wainwright","year":"2026","journal-title":"J Cyst Fibros"},{"key":"2026101013470021000_aamag370-B57","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1159\/000549098","article-title":"An amazing transformation!\u201d The lived experiences of elexacaftor\/tezacaftor\/ivacaftor in adults with cystic fibrosis","volume":"105","author":"Chapman","year":"2026","journal-title":"Respiration"},{"key":"2026101013470021000_aamag370-B58","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1164\/rccm.202411-2231OC","article-title":"Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in adults and adolescents with cystic fibrosis and at least one F508del allele: a phase 3 open-label extension study","volume":"211","author":"Daines","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"2026101013470021000_aamag370-B59","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.jcf.2024.03.005","article-title":"Symptoms and quality of life in adults with cystic fibrosis: a cross-sectional analysis of the InSPIRe: CF trial","volume":"23","author":"Smirnova","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2026101013470021000_aamag370-B60","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/thorax-2023-220100","article-title":"A refresh of the top 10 research priorities in cystic fibrosis","volume":"78","author":"Rowbotham","year":"2023","journal-title":"Thorax"},{"key":"2026101013470021000_aamag370-B61","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.jcf.2025.07.014","article-title":"Time out for an hour, every day, my whole life\u201d: understanding treatment burden in cystic fibrosis in the era of elexacaftor\/tezacaftor\/ivacaftor (ETI)","volume":"24","author":"Butcher","year":"2025","journal-title":"J Cyst Fibros"},{"key":"2026101013470021000_aamag370-B62","doi-asserted-by":"publisher","first-page":"e71190","DOI":"10.1002\/ppul.71190","article-title":"Baseline characteristics and self-reported use of chronic daily therapies of the home reported outcomes with CFTR modulator therapy (HERO-2) cohort","volume":"60","author":"Hergenroeder","year":"2025","journal-title":"Pediatr Pulmonol"},{"key":"2026101013470021000_aamag370-B63","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S2213-2600(22)00434-9","article-title":"Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials","volume":"11","author":"Mayer-Hamblett","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026101013470021000_aamag370-B64","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/S0140-6736(23)01608-2","article-title":"The future of cystic fibrosis treatment: from disease mechanisms to novel therapeutic approaches","volume":"402","author":"Graeber","year":"2023","journal-title":"Lancet"},{"key":"2026101013470021000_aamag370-B65","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1007\/s40262-025-01550-z","article-title":"A phase IIa, single-blind, placebo-controlled, parallel-group study to assess safety, tolerability, and pharmacokinetics\/pharmacodynamics of brensocatib in adults with cystic fibrosis","volume":"64","author":"Konstan","year":"2025","journal-title":"Clin Pharmacokinet"},{"key":"2026101013470021000_aamag370-B66","doi-asserted-by":"publisher","first-page":"2401551","DOI":"10.1183\/13993003.01551-2024","article-title":"Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF, a phase II randomised, double-blind, placebo-controlled, dose-finding study","volume":"65","author":"Chalmers","year":"2025","journal-title":"Eur Respir J"},{"key":"2026101013470021000_aamag370-B67","doi-asserted-by":"publisher","first-page":"240001","DOI":"10.1183\/16000617.0001-2024","article-title":"Neutrophil serine proteases in cystic fibrosis: role in disease pathogenesis and rationale as a therapeutic target","volume":"33","author":"Mall","year":"2024","journal-title":"Eur Respir Rev"},{"key":"2026101013470021000_aamag370-B68","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/art.1780350606","article-title":"Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE","volume":"35","author":"Bombardier","year":"1992","journal-title":"Arthritis Rheum"},{"key":"2026101013470021000_aamag370-B69","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1136\/ard.49.11.916","article-title":"Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score","volume":"49","author":"van der Heijde","year":"1990","journal-title":"Ann Rheum Dis"},{"key":"2026101013470021000_aamag370-B70","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.jcf.2025.06.003","article-title":"Pulmonary endpoints in clinical trials for children with cystic fibrosis under two years of age","volume":"24","author":"Lee","year":"2025","journal-title":"J Cyst Fibros"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/advance-article-pdf\/doi\/10.1093\/ajrccm\/aamag370\/68760277\/aamag370.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/212\/10\/2530\/68760277\/aamag370.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/212\/10\/2530\/68760277\/aamag370.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T17:47:11Z","timestamp":1791654431000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/212\/10\/2530\/8732668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":70,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,7,11]]},"published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajrccm\/aamag370","relation":{},"ISSN":["1535-4970"],"issn-type":[{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,7,11]]}}}